MONTVALE, N.J., Aug. 7, 2008 (PRIME NEWSWIRE) -- Ivivi Technologies, Inc. (Nasdaq:IVVI), a leader in non-invasive, electrotherapeutic technologies, today announced that management will discuss the Company's results for its 2009 fiscal first quarter ended June 30, 2008, during a conference call scheduled for Thursday, August 14, 2008 at 4:30 pm ET. The Company's financial results for its 2009 fiscal first quarter are scheduled to be released after the market closes on August 14, 2008 and prior to the conference call.
Shareholders and other interested parties may participate in the conference call by dialing (877) 407-0781 approximately 5 to 10 minutes before the beginning of the call. International callers should dial (201) 689-8568. If you are unable to participate, a replay of the call will be available until midnight on August 28, 2008 by dialing (877) 660-6853 and using pass code # 286 and conference ID # 293373. International callers should dial (201) 612-7415 and use the pass codes listed above. The call will also be broadcast live on the Investor Relations section of the Company's website www.ivivitechnologies.com and on www.InvestorCalendar.com. An archive of the call will also be available on the Company's website for 90 days.
About Ivivi Technologies, Inc.
Based in Montvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi's research and development activities are focused specifically on targeted pulsed electromagnetic field, or tPEMF(tm), technology, which, by creating a therapeutic electrical current in injured soft tissue, modulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company's Electroceuticals(r) have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders.